Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at a ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...